Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The advent of NIS-based <i>in vivo</i> imaging and theranostic strategies in other malignancies and disease modalities has recently increased the clinical importance of NIS.
|
31672844 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
NIS in cancer patients has primarily been recorded to be a cytoplasmic protein, thus limiting the scope for targeted radio-iodine therapy.
|
31455607 |
2019 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In summary, our results elucidate a pump-independent, protumorigenic role for NIS in thyroid cancer via its cross-talk with PTEN signaling.<b>Significance:</b> A novel pump-independent protumorigenic role of nonmembranous NIS challenges the presumption that radioiodine treatment of thyroid cancer is ineffective when transmembrane NIS is not expressed.<i>Cancer Res; 78(21); 6121-33.©2018 AACR</i>.
|
30217930 |
2018 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
mRNA Expression of SLC5A5 and SLC2A Family Genes in Papillary Thyroid Cancer: An Analysis of The Cancer Genome Atlas.
|
29978611 |
2018 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A comparative oncology study was carried out to investigate feasibility and tolerability of intravenous oncolytic VSV-IFNβ-NIS therapy in pet dogs with spontaneous cancer.
|
29158470 |
2018 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Given the highly significant role of NIS in the physiology and the cancer pathogenesis process, this paper's objective is to provide a comprehensive assessment of the associations between NIS gene and protein with papillary thyroid cancer.
|
30595693 |
2018 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This promising gene therapy approach opens the exciting prospect of NIS-mediated radionuclide therapy in metastatic cancer, together with the possibility of combining several targeting ligands to enhance selective therapeutic efficacy in a broad field of cancer types with various receptor expression profiles.
|
28423213 |
2017 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The sodium iodide symporter (NIS) as well-characterized theranostic gene represents an outstanding tool to target different cancer types allowing noninvasive imaging of functional NIS expression and therapeutic radioiodide application.
|
27157666 |
2016 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Clinical translation of VSV-IFNβ-NIS is underway in companion dogs with cancer and in human patients with relapsed hematological malignancies and endometrial cancer.
|
27532609 |
2016 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The sodium iodine symporter (NIS) gene has often been used in cancer therapy and imaging.
|
27573304 |
2016 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The sodium iodine symporter (NIS) gene has been applied for in vivo imaging and cancer therapy.
|
25621996 |
2015 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Therefore, enhancing functional NIS by the increasing level of glycosylation may be suggested as a promising therapeutic strategy for cancer patients who show refractory response to conventional radioiodine treatment.
|
26599396 |
2015 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This review describes recent findings in NIS research in extrathyroidal malignancies, focusing on breast and urological cancer, emphasizing the most relevant developments that may have clinical impact.
|
24884806 |
2014 |
Malignant Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
The results of this study showed that methylation of NIS promoter is a very frequent event in both benign and malignant tumors as well as in their surrounding tissues, and characterized a non-homogeneous methylation pattern along the CpG island.
|
22945693 |
2013 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Sodium iodide symporter (NIS)-based radionuclide therapy provides an effective means of treating malignant tumors.
|
22301953 |
2012 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The aim of this study was to investigate the NIS-mediated therapeutic effect of telomerase promoters in a wide variety of human cancer cell lines.
|
21697253 |
2011 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
To test the feasibility of using the survivin promoter to induce specific expression of sodium/iodide symporter (NIS) in cancer cell lines and tumors for targeted use of radionuclide therapy, a recombinant adenovirus, Ad-SUR-NIS, that expressed the NIS gene under control of the survivin promoter was constructed.
|
21037556 |
2011 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We have extended the use of NIS-mediated radioiodine therapy to other types of cancer, we transferred and expressed the NIS gene into prostate, colon and breast cancer cells using adenoviral vectors.
|
20428214 |
2010 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
To extend the use of NIS-mediated radioiodine therapy to other types of cancer, we successfully transferred and expressed the sodium-iodide symporter (NIS) gene in prostate, colon, and breast cancer cells both in vivo and in vitro by using non-replicating adenoviral vectors.
|
19635153 |
2009 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
|
19861538 |
2009 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Although the success of sodium/iodide symporter (NIS) gene-based cancer therapy is critically dependent on the level of radioiodide accumulation attained, recent evidence indicates that successful therapy relies not solely on NIS amount but also crucially on its functional activity.
|
18997042 |
2008 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Radioiodide imaging and treatment of ARO cancer xenograft in a mouse model after expression of human sodium iodide symporter.
|
17695547 |
2007 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This study shows that the weak preventive effects of cancer DNA vaccine can be overcome by radioiodine gene therapy utilizing sodium iodide symporter.
|
17565743 |
2007 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our study indicates that (211)At represents a promising substrate for NIS-mediated therapy of various cancers either with endogenous or gene transfer-mediated NIS expression.
|
16489092 |
2006 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Other types of cancer could also be treated by NIS-mediated concentration of lethal (131)I radiation in tumor cells.
|
16525480 |
2006 |